Mortality predictors and prognostic implications of intermittent levosimendan therapy in advanced heart failure

11 May 2026 (13:00 - 14:07)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Rodrigo Brandao

Hospital Professor Doutor Fernando Fonseca, Amadora (Portugal)

7 More presentations in this session

Presentation thumbnail

Exploring medication adherence in heart failure from a patient perspective - a qualitative study

Mrs I. Gunnthorsdottir (Reykjavik, IS)

Abstract Slides

Presentation thumbnail

Impact of optimized guideline-directed medical therapy on mortality in octogenarians with heart failure and reduced ejection fraction: a real-world cohort study

Doctor E. Amao Ruiz (Reus, ES)

Abstract Slides

Presentation thumbnail

An interim report from a year in the life of a heart failure patient project: medication adjustment patterns at 3 and 6 months

Ms E. Brennan (Dublin, IE)

Abstract Slides

Presentation thumbnail

Cardiac cachexia as a key determinant of clinical stability in advanced heart failure patients treated with intermittent levosimendan

Doctor R. Brandao (Amadora, PT)

Abstract Slides

Presentation thumbnail

Sustained clinical stability and quality of life with intermittent levosimendan: a real-world experience of over 550 administrations

Doctor R. Brandao (Amadora, PT)

Abstract Slides

Access the full session

Session thumbnail

ePosters in chronic heart failure - pharmacotherapy (3)

The Event

Event poster

Heart Failure 2026

11 May 2026 13:00 CET

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Presentation

Audience Q&A

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources